That could very well be the case for most PP investors but I believe the company has used at least two different Non-Disclosure Statements for Private Placement investors. I do not know how the criteria differed.
Some investors did agree to a lock-up period as a condition of their investment in Neurotrope. For instance Dr Abeles and Northlea Partners own a substantial interest in NTRP and may or may not have had access to non-public or insider information:
Prospectus Supplement is April 12, 2016
“On November 12, 2015, we entered into a lock-up agreement with Dr. John Abeles and Northlea Partners LLLP. Pursuant to the terms of the lock-up agreement, Dr. John Abeles and Northlea Partners LLLP agreed not to pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of our Series B Stock and Series A through Series E warrants, or any securities underlying, convertible into or exercisable or exchangeable for our Series B Stock and Series A through Series E warrants. The lock-up agreement will automatically terminate upon the second anniversary of the date of the final closing relating to the offering of our Series B Stock and Series A through Series E warrants.”
News 
Market Data 
Discover 
AI
